The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Rat EBI3 ORF mammalian expression plasmid, C-GFPSpark tag||RG80427-ACG|
|Rat EBI3 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80427-ACR|
|Rat EBI3 ORF mammalian expression plasmid, C-Flag tag||RG80427-CF|
|Rat EBI3 ORF mammalian expression plasmid, C-His tag||RG80427-CH|
|Rat EBI3 ORF mammalian expression plasmid, C-Myc tag||RG80427-CM|
|Rat EBI3 ORF mammalian expression plasmid, C-HA tag||RG80427-CY|
|Rat EBI3 ORF mammalian expression plasmid, N-Flag tag||RG80427-NF|
|Rat EBI3 ORF mammalian expression plasmid, N-His tag||RG80427-NH|
|Rat EBI3 ORF mammalian expression plasmid, N-Myc tag||RG80427-NM|
|Rat EBI3 ORF mammalian expression plasmid, N-HA tag||RG80427-NY|
|Rat EBI3 natural ORF mammalian expression plasmid||RG80427-UT|
|Learn more about expression Vectors|
The novel Ebi3-IL-12alpha heterodimeric cytokine has been designated interleukin-35 (IL-35), is a member IL12 family cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of IL-12α (P35) and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory cytokine that may be specifically produced by T(reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4(+)CD25(+)Foxp3(+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory cytokine, along with TGFbeta cytokine. IL-35 is a cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.